. 2016 Jan 7;4:e1542. doi: 10.7717/peerj.1542

Table 2. IC₅₀ values (μM) of doxorubicin (DOX) and cisplatin (CIS) in arginine-rich media (ARM) and arginine-free media (AFM).

N°	Cells	DOX (IC₅₀ ± SD)		CIS (IC₅₀ ± SD)
N°	Cells	ARM	AFM	ARM	AFM
1.	HeLa	1.66 ± 0.30^*	4.07 ± 0.26^*	77.36 ± 9.11^*	54.07 ± 12.25^*
2.	Caco-2	33.55 ± 4.93	34.91 ± 5.70	105.88 ± 14.66	96.38 ± 32.03
3.	MIA PaCa-2	14.60 ± 1.21	22.25 ± 3.35	72.01 ± 3.50	97.20 ± 20.34
4.	BxPC-3	5.00 ± 0.74^*	6.90 ± 0.53^*	126.42 ± 34.07^*	85.66 ± 3.81^*
5.	Hep G2	1.86 ± 0.38^*	4.68 ± 1.08^*	23.99 ± 2.75^*	14.87 ± 1.22^*
6.	SK-HEP-1	7.92 ± 2.43^*	11.09 ± 0.82^*	117.40 ± 15.72	77.89 ± 17.77

Note:

Data from three independent experiments (n = 3) are represented as mean ± SD. The asterisk indicates a significant difference (at P < 0.05 analyzed using t-Test) in the cytotoxicity of the chemotherapeutic drug in cancer cells treated with arginine rich media (ARM) compared with arginin free media (AFM).

Table 2. IC50 values (μM) of doxorubicin (DOX) and cisplatin (CIS) in arginine-rich media (ARM) and arginine-free media (AFM).

Table 2. IC₅₀ values (μM) of doxorubicin (DOX) and cisplatin (CIS) in arginine-rich media (ARM) and arginine-free media (AFM).